EndoPredict is a second-generation, multigene prognostic test kit for patientsdiagnosed with breast cancer. Under the agreement, Myriad will receive comprehensive marketing rights todistribute and sell EndoPredict, including in high-growth markets in Europe.The agreement will leverage Myriad's 45-person international commercial teamand will significantly increase the number of medical specialists and salesprofessionals supporting EndoPredict. Specific terms of the deal were notdisclosed. EndoPredict provides physicians with information to devise personalizedtreatment plans for their breast cancer patients. The EndoPredict test kitformat is an ideal platform for use by clinical pathologists, who desire toconduct testing within their own laboratories. In contrast to older multi-genetests, EndoPredict detects the likelihood of late metastases (i.e., metastasisformation after more than five years) and can thus guide treatment decisionsfor chemotherapy as well as extended anti-hormonal therapy. Accordingly,therapy decisions backed by EndoPredict confer a high level of diagnosticsafety. EndoPredict was shown to accurately predict cancer-specific diseaseprogression and metastasis in multiple clinical outcome studies with more than2,200 patients. 'Myriad has a significant opportunity to leverage our international presence,and we are pleased to be partnering with Sividon to make EndoPredict even morewidely available to patients in Europe and worldwide,' said Gary King,Executive Vice President, International Operations, Myriad Genetics. 'We arecommitted to contributing to the health of people in Europe through a strongsales and marketing organization that provides enhanced access to life-savingproducts for patients and cost effective solutions for healthcare providers.Myriad's team of field specialists will support EndoPredict's current customersin liaison with Sividon's medical expert team, thus providing additional levelsof support and contact.' 'Sividon's EndoPredict, backed by compelling evidence from clinical studieswith thousands of patients combined with Myriad's strong commercial capabilityand coverage in many key countries creates an outstanding partnership,' saidDr. Christoph Petry, CEO of Sividon Diagnostics. 'Breast cancer affects thelife of more than 388,000 women per year in Europe, and EndoPredict will helpto significantly improve their cancer treatment. We are delighted to partnerwith Myriad to help save and improve the lives of more women with breastcancer.' About Myriad Genetics GmbHMyriad Genetics GmbH is based in Zurich, Switzerland and is the internationalsubsidiary of Myriad Genetics Inc., a leading molecular diagnostic companydedicated to making a difference in patients' lives through the discovery andcommercialization of transformative tests to assess a person's risk ofdeveloping disease, guide treatment decisions and assess risk of diseaseprogression and recurrence. Myriad's molecular diagnostic tests are based on anunderstanding of the role genes play in human disease and were developed with acommitment to improving an individual's decision making process for monitoringand treating disease. Myriad is focused on strategic directives to introducenew products, including companion diagnostics, as well as expandinginternationally. For more information on how Myriad Genetics GmbH is making adifference, please visit the Company's website: http:\/\/www.myriad.ch<\/a>. Myriad and theMyriad logo are trademarks or registered trademarks of Myriad Genetics, Inc. inthe United States and worldwide. MYGN-F, MYGN-G About SividonSividon Diagnostics GmbH was founded in 2010 as a management buyout fromSiemens Healthcare Diagnostics in Cologne, Germany. Sividon is dedicated todevelop modern methods for the molecular pathology laboratory to help improvethe quality of care for cancer patients. Sividon's first product, EndoPredict,has been introduced into the market in 2011 and allows for a moreindividualized therapy management in breast cancer. For more information onSividon please visit the Sividon's website at http:\/\/www.sividon.com<\/a>. Sividon, theSividon logo and EndoPredict are registered trademarks of Sividon DiagnosticsGmbH in Germany and other countries. Safe Harbor StatementThis press release contains 'forward-looking statements' within the meaning ofthe Private Securities Litigation Reform Act of 1995, including statementsrelating to the EndoPredict test and Myriad's partnering with Sividon to marketthe EndoPredict test in Europe and worldwide; and the Company's strategicdirectives under the caption 'About Myriad Genetics.' These 'forward-lookingstatements' are management's present expectations of future events and aresubject to a number of risks and uncertainties that could cause actual resultsto differ materially and adversely from those described in the forward-lookingstatements. These risks include, but are not limited to: the risk that salesand profit margins of our existing molecular diagnostic tests and companiondiagnostic services may decline or will not continue to increase at historicalrates; risks related to changes in the governmental or private insurersreimbursement levels for our tests; the risk that we may be unable to developor achieve commercial success for additional molecular diagnostic tests andcompanion diagnostic services in a timely manner, or at all; the risk that wemay not successfully develop new markets for our molecular diagnostic tests andcompanion diagnostic services, including our ability to successfully generaterevenue outside the United States; the risk that licenses to the technologyunderlying our molecular diagnostic tests and companion diagnostic servicestests and any future tests are terminated or cannot be maintained onsatisfactory terms; risks related to delays or other problems with opeRatingour laboratory testing facilities; risks related to public concern over ourgenetic testing in general or our tests in particular; risks related toregulatory requirements or enforcement in the United States and foreigncountries and changes in the structure of the healthcare system or healthcarepayment systems; risks related to our ability to obtain new corporatecollaborations or licenses and acquire new technologies or businesses onsatisfactory terms, if at all; risks related to our ability to successfullyintegrate and derive benefits from any technologies or businesses that welicense or acquire; risks related to increased competition and the developmentof new competing tests and services; the risk that we or our licensors may beunable to protect or that third parties will infringe the proprietarytechnologies underlying our tests; the risk of patent-infringement claims orchallenges to the validity of our patents; risks related to changes inintellectual property laws covering our molecular diagnostic tests andcompanion diagnostic services and patents or enforcement in the United Statesand foreign countries, such as the Supreme Court decision in the lawsuitbrought against us by the Association for Molecular Pathology et al; risks ofnew, changing and competitive technologies and regulations in the United Statesand internationally; and other factors discussed under the heading 'RiskFactors' contained in Item 1A of our most recent Annual Report on Form 10-Kfiled with the Securities and Exchange Commission, as well as any updates tothose risk factors filed from time to time in our Quarterly Reports on Form10-Q or Current Reports on Form 8-K. All information in this press release isas of the date of the release, and Myriad undertakes no duty to update thisinformation unless required by law. CONTACT: Media Contacts:Ron Rogers(801) 584-3065rrogers@myriad.comEstherLinnenberg<\/a>+49-221-66956170linnenberg@sividon.comInvestor Contact:ScottGleason(801) 584-1143sgleason@myriad.comNews<\/a> Source: NASDAQ OMXEnd of Corporate News---------------------------------20.01.2014 Dissemination of a Corporate News, transmitted by DGAP - acompany of EQS Group AG.The issuer is solely responsible for the content of this announcement.DGAP's Distribution Services include Regulatory Announcements,Financial\/Corporate News and Press Releases.Media archive at http:\/\/www.dgap-medientreff.de<\/a> and http:\/\/www.dgap.de---------------------------------Language<\/a>: English Company: Myriad Genetics, Inc. United States ISIN: US62855J1043 End of News DGAP News-Service --------------------------------- 248572 20.01.2014 <\/p>\n<\/p>\n Myriad Genetics <\/p>\n Aktuelle Diskussionen zum Thema: <\/p>\n Myriad - gehts wieder aufwrts? (13.05.13) mal ber Myriad nachgedacht ? (03.07.07) Boardumfrage (an Alle) (04.01.05) <\/p>\n Aktuelle Nachrichten zum Unternehmen: <\/p>\n Myriad Genetics steigert Gewinn, . (11.08.10) Myriad Genetics verbucht deutliche. (04.11.08) Myriad Genetics prft Abspaltung . (11.09.08) Myriad Genetics verbucht krftiges. (19.08.08) <\/p>\n Alle Nachrichten zum Unternehmen <\/p>\n Aktuelle Analysen zu den Unternehmen: <\/p>\n Myriad Genetics<\/p>\n <\/p>\n Read more from the original source:<\/p>\n Myriad Genetics and Sividon Diagnostics Announce Exclusiv.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" EndoPredict is a second-generation, multigene prognostic test kit for patientsdiagnosed with breast cancer. Under the agreement, Myriad will receive comprehensive marketing rights todistribute and sell EndoPredict, including in high-growth markets in Europe.The agreement will leverage Myriad's 45-person international commercial teamand will significantly increase the number of medical specialists and salesprofessionals supporting EndoPredict. Specific terms of the deal were notdisclosed Continue reading